{"id":33837,"date":"2025-05-21T20:09:37","date_gmt":"2025-05-21T12:09:37","guid":{"rendered":"https:\/\/flcube.com\/?p=33837"},"modified":"2025-05-21T20:09:38","modified_gmt":"2025-05-21T12:09:38","slug":"yifan-pharma-licenses-ryzneuta-to-lenis-for-balkan-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33837","title":{"rendered":"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets"},"content":{"rendered":"\n

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019<\/a>) announced a licensing agreement with Lenis, a Slovenian-based full-service regional distributor of niche and specialty Rx medicines, for its Ryzneuta (efbemalenograstim alfa, F-627). Under the agreement, Lenis will be responsible for market planning and sales of the drug in Croatia, Slovenia, Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia, with option rights in the Czech Republic, Slovakia, Bulgaria, and Hungary.<\/p>\n\n\n\n

Agreement Details<\/strong>
Yifan Pharma will generate international revenue by selling the product to Lenis, in addition to receiving upfront and milestone payments. Lenis will handle pricing, reimbursement, marketing, distribution, and other related matters for the product. Yifan Pharma will supply the product and provide necessary training and support for related brands.<\/p>\n\n\n\n

Ryzneuta Technology and Mechanism<\/strong>
Ryzneuta is a rhG-CSF developed via Yifan’s proprietary Di-Kine bimolecular technology platform. It features long-lasting and potent biological characteristics, primarily functioning as a “leukopoietic agent.” The drug is used to prevent and treat chemotherapy-induced neutropenia in cancer patients, promoting rapid proliferation and recovery of neutrophils. This mechanism enhances the immune system’s ability to combat infections, helping patients avoid complications during chemotherapy treatment.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based…<\/p>\n","protected":false},"author":1,"featured_media":33841,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,4085,1281,563],"class_list":["post-33837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-lenis","tag-she-002019","tag-yifan-pharmaceutical"],"yoast_head":"\nYifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based full-service regional distributor of niche and specialty Rx medicines, for its Ryzneuta (efbemalenograstim alfa, F-627). Under the agreement, Lenis will be responsible for market planning and sales of the drug in Croatia, Slovenia, Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia, with option rights in the Czech Republic, Slovakia, Bulgaria, and Hungary.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33837\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets\" \/>\n<meta property=\"og:description\" content=\"China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based full-service regional distributor of niche and specialty Rx medicines, for its Ryzneuta (efbemalenograstim alfa, F-627). Under the agreement, Lenis will be responsible for market planning and sales of the drug in Croatia, Slovenia, Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia, with option rights in the Czech Republic, Slovakia, Bulgaria, and Hungary.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33837\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-21T12:09:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T12:09:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets\",\"datePublished\":\"2025-05-21T12:09:37+00:00\",\"dateModified\":\"2025-05-21T12:09:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837\"},\"wordCount\":200,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2101-1.webp\",\"keywords\":[\"Cancer\",\"Lenis\",\"SHE: 002019\",\"Yifan Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33837#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33837\",\"name\":\"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2101-1.webp\",\"datePublished\":\"2025-05-21T12:09:37+00:00\",\"dateModified\":\"2025-05-21T12:09:38+00:00\",\"description\":\"China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based full-service regional distributor of niche and specialty Rx medicines, for its Ryzneuta (efbemalenograstim alfa, F-627). Under the agreement, Lenis will be responsible for market planning and sales of the drug in Croatia, Slovenia, Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia, with option rights in the Czech Republic, Slovakia, Bulgaria, and Hungary.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33837\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2101-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2101-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33837#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets - Insight, China's Pharmaceutical Industry","description":"China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based full-service regional distributor of niche and specialty Rx medicines, for its Ryzneuta (efbemalenograstim alfa, F-627). Under the agreement, Lenis will be responsible for market planning and sales of the drug in Croatia, Slovenia, Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia, with option rights in the Czech Republic, Slovakia, Bulgaria, and Hungary.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33837","og_locale":"en_US","og_type":"article","og_title":"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets","og_description":"China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based full-service regional distributor of niche and specialty Rx medicines, for its Ryzneuta (efbemalenograstim alfa, F-627). Under the agreement, Lenis will be responsible for market planning and sales of the drug in Croatia, Slovenia, Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia, with option rights in the Czech Republic, Slovakia, Bulgaria, and Hungary.","og_url":"https:\/\/flcube.com\/?p=33837","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-21T12:09:37+00:00","article_modified_time":"2025-05-21T12:09:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33837#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33837"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets","datePublished":"2025-05-21T12:09:37+00:00","dateModified":"2025-05-21T12:09:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33837"},"wordCount":200,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33837#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101-1.webp","keywords":["Cancer","Lenis","SHE: 002019","Yifan Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33837#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33837","url":"https:\/\/flcube.com\/?p=33837","name":"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33837#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33837#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101-1.webp","datePublished":"2025-05-21T12:09:37+00:00","dateModified":"2025-05-21T12:09:38+00:00","description":"China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based full-service regional distributor of niche and specialty Rx medicines, for its Ryzneuta (efbemalenograstim alfa, F-627). Under the agreement, Lenis will be responsible for market planning and sales of the drug in Croatia, Slovenia, Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia, with option rights in the Czech Republic, Slovakia, Bulgaria, and Hungary.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33837#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33837"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33837#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101-1.webp","width":1080,"height":608,"caption":"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33837#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33837"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33837\/revisions"}],"predecessor-version":[{"id":33842,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33837\/revisions\/33842"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33841"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}